*Refresh the page if the below document does not appear.
Alkem Labs launches its over-the-counter cell therapy for Knee Osteoarthritis
Alkem Laboratories recently announced that StemOne received the approval from DCGI (Drug Controller General of India) to launch the first allogenic cell therapy product for commercial use in India.
Aragen Life Sciences partners with NeoVac to develop lipid product
Hyderabad-based company signed an agreement with a UK based company named NeoVac, which has been working on the PRD (process research development) to develop Lipid nanoparticles (LNP) used to prepare RNA vaccines for many diseases.
Indoco Remedies rises after clearing inspection without receiving 483
The company soared by 4.08% to Rs 368.95 after it declared that its CRO (Clinical Research Organization) AnaCipher has successfully cleared US FDA inspection without the issuance of a single 483 observation.
US regulatory authority restarts surprise inspections in India
US FDA has increased its inspection activities in India and have plans of conducting more surprise or short notice inspections bringing the drugmakers enjoyment period that began with the onset of COVID-19 to an end.
Drugmakers faces claims for cancer types not included in federal action for Zantac litigation
Federal litigation mentions five types of Cancer allegedly caused by the consumption of the drug, but concern arises when litigators who used Zantac are filing lawsuits mentioning other kinds of Cancer.
Bangladeshi pharma industry Post LDC graduation
There is a strong need to develop Bangladeshi Pharma industry while its transitioning out of LDC (Least Developed Countries). Only 1.94% of total foreign direct investment in Bangladesh comes from Pharmaceuticals and chemicals which must be increased.
Natco Pharma receives approval from Delhi HC to launch CTPR
Chlorantraniliprole (CTPR) technology is used
in the formulation of this broad-spectrum
insecticide that can be used to control pests in
different types of crops. An approval for this
technology resulted in a rise of the company’s
stocks by 2.5%.
